Enoxaparin sodium

Drug Profile

Enoxaparin sodium

Alternative Names: Clexane; Decipar; Enoxaparin; Enoxaparin Pen; Klexane; Levenox; Lovenox; PK 10169; PRY 005; RP 54563; RPY 005

Latest Information Update: 25 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pharmuka
  • Developer G.L. Pharma; Italfarmaco; Sanofi
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Embolism; Myocardial infarction; Thromboembolism; Thrombosis; Unstable angina pectoris
  • Phase III Small cell lung cancer

Most Recent Events

  • 21 Jul 2017 Jury in the District Court for the District of Massachusetts in Boston issues verdict accepting patent infringement but finding it invalid and unenforceable in lawsuit filed against Amphastar by Momenta Pharmaceuticals regarding generic enoxaparin sodium injection in USA
  • 15 Mar 2016 Biomarkers information updated
  • 03 Nov 2014 Enoxaparin sodium is still in a phase III trial for Small cell lung cancer in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top